Open-label study to evaluate the tolerability, safety and efficacy of the equimolar conversion from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPS) in patients with renal transplant

Trial Profile

Open-label study to evaluate the tolerability, safety and efficacy of the equimolar conversion from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPS) in patients with renal transplant

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Feb 2011

At a glance

  • Drugs Mycophenolate mofetil; Mycophenolate sodium
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 01 Feb 2011 Actual end date (Jun 2005) added as reported by ClinicalTrials.gov.
    • 01 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top